Adoptive immunotherapy is the isolation and infusion of antigen-specific or nonspecific lymphocytes. Adoptive therapy with T cells may have a role in replacing, repairing, or enhancing immune function damaged by cytotoxic therapies, and rapid lymphocyte recovery may improve outcome after autologous and allogeneic stem cell transplantation (SCT). Recently, a plethora of information on the basic mechanisms of T-cell biology and regulation of cellular immune responses has emerged, permitting the development of new forms of adoptive cell therapy. Efficient ex vivo culture method for T-cell subsets affords the possibility of adoptive transfer of T cells engineered with enhanced capacity for central memory, effector cytotoxicity, Th1, Th2, veto cell, and T regulatory functions. Studies show that homeostatic Tcell proliferation is important for effective adoptive immunotherapy and pretreatment with chemotherapy may enhance the effects of infused T cells. Replicative senescence, in part due to telomere erosion, likely limits successful adoptive immunotherapy, though it may be possible to maintain T-cell pools by enforced expression of telomerase. Clinical trials now demonstrate that it is possible to enhance immune reconstitution after SCT with cytokines or infusions of ex vivo costimulated expanded T cells. These data all support the premise that adoptive therapy can accelerate reconstitution of cellular immunity with enhanced antitumor effects following SCT. Bone Marrow Transplantation (2005) 35, 935-942.
infusions; T cells A study of immunologic memory of women who have recovered from a single exposure to hepatitis C infection revealed that T-cell memory persisted for at least two decades while humoral responses had waned. 1 Patients subjected to stem cell transplantation (SCT) procedures have lost this T-cell 'memory bank', and are severely immunocompromised after transplantation, [2] [3] [4] resulting in an increased risk of infectious complications and compromised tumor immunosurveillance. The infusion of large numbers of hematopoietic progenitor cells during a SCT procedure is not sufficient to restore cell immune competence. 5 As a consequence, a central issue with SCT is the inability to successfully carry out vaccination in SCT recipients. 6 At least in part, the depletion of T cells and thymic damage consequent to conditioning for SCT leads to delayed T-cell reconstitution, 7, 8 and the eventual recovery of immune function after SCT correlates with thymic rebound. 9 Recent studies suggest that higher absolute lymphocyte counts shortly after SCT correlates with improved DFS and/ or overall survival. [10] [11] [12] [13] [14] The rate of immune reconstitution in patients with ovarian cancer after high-dose chemotherapy is an independent marker of time to progression, 15 and this may be related to the recent finding that immunosurveillance as assessed by the presence of tumor infiltrating lymphocytes (TILs) at the time of diagnosis is a strong predictor of disease-free survival in ovarian cancer. 16 It is likely that rapid recovery of T-cell function after SCT is critical for protection against infections and to promote graft-versustumor (GVT) activity. It is also likely that acceleration of Tcell recovery, or infusions of mature T cells, would minimize immune suppression and improve outcome of autologous or allogeneic SCT. Table 1 lists some of the major issues facing the field that are currently being addressed to improve adoptive cell transfer therapy and the ability to accelerate immune recovery and improve antitumor immunity after SCT.
Homeostatic lymphocyte proliferation and memory
Recent studies indicate that T-cell survival in the periphery is dependent on continuous delivery of environmental signals. The nature of the survival signals that are required appears to differ between naı¨ve and memory T cells, and between CD4 þ and CD8 þ T cells. 17, 18 The adoptive transfer of T cells into lymphopenic mice enhances the efficacy of antitumor responses over that observed in lymphocyte replete hosts. 19 In humans, recent studies indicate that homeostatic T-cell proliferation may enhance the efficacy of adoptive cell transfer strategies. 20, 21 Human CD8 effector memory T cells can be differentiated in vitro from central memory cells upon homeostatic proliferation in the absence of antigen. 22 There are numerous biochemical differences between T-and B-cell memory. For example, unlike B cells, T cells lacking antigen receptors do not die precipitously. 23 Studies with transgenic mice have shown that central memory cells require calcium/calmodulin kinase II (CaM-KII) while naı¨ve T cells do not. 24 Naive CD4 T cells must traffic through secondary lymphoid organs to maintain a stable CD4 pool as the naive CD4 but not CD8 T-cell population is dependent on the presence of secondary lymphoid tissues. 23, 25 Of potential relevance to SCT, a procedure that accelerates immune aging, 26 old mice have defective generation but normal maintenance of memory T cells. 27 A large body of literature indicates that chemotherapy enhances the effectiveness of adoptively transferred T cells. 28 Multiple reasons, including the induction of homeostatic proliferation, appear to account for this observation. Chemotherapy may ablate cells and create niches for the adoptively transferred cells. However, the 'space' argument is likely a minor factor as other studies indicate that a major effect of chemotherapy is to ablate suppressor or regulatory T cells that inhibit the effects of adoptively transferred T cells. 29 Finally, chemotherapy may enhance the effectiveness of adoptively transferred T cells by killing tumor, leading to enhanced antigen presentation on bone marrow derived APC and the subsequent loss of immunologic tolerance or ignorance to tumor. 30, 31 Replicative senescence
T cells have finite clonal lifespans in vitro,
32 a phenomenon also manifested with other somatic tissue cells and that is commonly known as the Hayflick Limit. In vitro, the current limit of polyclonal expansion for adult mature T cells is about 30 to 40 population doublings. [33] [34] [35] One aspect of replicative senescence is telomere erosion consequent to multiple cell divisions and cellular stress. 36 Lymphocytes and stem cells belong to a select class of cells that have the capacity for regulated induction of telomerase activity, 37 which may delay onset of replicative senescence.
Replicative senescence could have important implications for adoptive immunotherapy with T cells, particularly in the case of antigen-specific T cells. For example, in order to obtain a billion clonal T cells of a desired specificity from a single naive T cell, 27 population doublings are required. Given that most culture systems contain a significant fraction of apoptotic cells, substantially more than 27 cell divisions are required in order to obtain a billion T cells. It is likely that many previous clinical adoptive immunotherapy trials have been unsuccessful because the prolonged ex vivo culture process resulted in a population of cells that had reached replicative senescence. Consistent with this 40 a strategy that may increase the efficacy of adoptive transfer approaches.
Engraftment
Adoptive immunotherapy with ex vivo-expanded antigenspecific CTLs has been shown to clear viral infections and eliminate tumors in murine models. In human clinical trials, there is promising data for the use of adoptive immunotherapy to treat infections with human immunodeficiency virus type 1 (HIV-1), and cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in bone marrow transplant recipients. For therapy of these viral infections, the need for ex vivo-expanded CTLs is often short lived, until the donor transplant reconstitutes the host immune system. In contrast, in HIV-1 and in cancer therapy, longterm engraftment of adoptively transferred CTLs and generation of memory will be necessary. In fact, one major rationale for adoptive immunotherapy is that it establishes a long-lasting memory to provide an ongoing immunosurveillance function. 1 In the case of T cells, memory is manifested by the clonal survival of the effector cells. The survival of mature T cells is an active process and depends on either biochemical signals derived from the T-cell receptor or from cytokines. Naı¨ve T cells require T-cell receptor interactions with the self-MHC molecules that are expressed on APC, while memory T cells survive independent of MHC interactions, and at least in the case of mouse CD8
þ CTLs, survival is dependent on IL-7 and IL-15. 41, 42 Given the concept of clonal persistence, the definition of lifespan for T lymphocytes is confusing and can either be taken as the time to cell division (ie intermitotic survival time) or as the time to cell death. Clonal persistence can be attributed to two distinct mechanisms: the presence of noncycling long-lived cell populations or through continued self-renewal by cycling cells. Studies indicate that T cells employ both mechanisms. 43, 44 Until recently, it was not possible to safely measure T-cell survival in humans. However, it is now possible to label lymphocytes with deuterated glucose, a nonradioactive stable isotope-enriched precursor, to measure DNA replication. 45 Recent measurements using this technique indicate that the halflives in normal adults of CD4 þ T cells and CD8 þ T cells are 87 and 77 days, respectively. 46 Indeed, several studies that employ distinct techniques to measure lymphocyte lifespans in primates have concluded that CD8 þ T-cell turnover is slightly more rapid than CD4 þ T-cell turnover.
The survival of different functional T-cell subsets also varies, as studies following the disappearance rates of cells with radiation-induced chromatin damage indicate that naı¨ve T cells have a longer intermitotic survival, estimated at division occurring on average every 3.5 years, while memory cells divide on average every 22 weeks. 47 In HIV-1 infected adults on antiretroviral therapy, deuterated glucose measurements indicate that the half-lives of naive-phenotype T cells ranges from 116 to more than 365 days, whereas T cells of the memory/effector-phenotype persisted with half-lives from 22 to 79 days. 48 T cells are different from most other tissues such as in the case of red blood cells where survival is related to lifespan of the cells and the oldest cells are removed first. The majority of T cells induced following an antigenic challenge die while still 'young' through activation-induced cell death, as a consequence of the need to maintain T-cell homeostasis both at the total population number as well as at the clonal level. 43 Several studies have assessed the engraftment of adoptively transferred T cells in patients with immunodeficiency. Gene-modified autologous T cells have been shown to survive for greater than 8 years in two patients with adenosine deaminase deficiency. 49 T cells marked with the gene encoding neomycin phosphotransferase have been shown to persist for more than 4 months after adoptive transfer to bone marrow allograft recipients. 50 Surprisingly, neomycin or hygromycin-marked syngeneic or autologous T cells initially engraft but do not persist long term in most patients with HIV-1 infection, due to immune-mediated rejection of the gene marked cells. 51, 52 When adoptively transferred polyclonal mixtures of CD4 þ and CD8 þ T cells are infused in HIV-1-infected patients, the frequency of retrovirally marked cells 2 weeks following infusion was 41%, and the level remained essentially unchanged for at least 6 months. The reasons for the enhanced efficiency of engraftment in this study were due to technical changes in ex vivo culture of the cells, as well as the fact that the CD4 þ T cells provide helper effects to increase CD8 T-cell survival and function. 53, 54 Adoptive T-cell transfer in cancer patients
The engraftment efficiency of adoptively transferred T cells in humans has been assessed in recent clinical studies of melanoma patients. In early studies in which TILs were retrovirally transduced with the neomycin gene, the frequency of adoptively transferred cells represented about 1% of peripheral blood mononuclear cells (PBMC) 1 h after infusion; however, the frequency fell to less than 1/ 10 000 PBMC within a week after infusion, and trafficking to tumor sites was inefficient. 55 More recent studies used tetramers to track the persistence of adoptively transferred antigen-specific CTL clones in patients with melanoma. They found that the transferred cells achieved initial frequencies of at least 1/800 PBMCs in the peripheral blood, and that the median survival of the transferred CTLs was approximately 7 days. 56 If patients were given low-dose IL-2 (500 000 U/m 2 /day), then the median survival of the CTL was enhanced. The persistence of adoptively transferred T cells correlates with tumor regression in patients with melanoma. 57 If clonal populations of CD8 cells are being infused, then treatment of the patient with IL-2 can extend survival of the cells. However, if the cells have been cultured ex vivo for prolonged times in high concentrations of IL-2, they have shortened survival in vivo due to apoptosis from growth factor withdrawal. IL-2 infusions do not enhance the survival of adoptively transferred populations of T cells that contain adequate numbers of CD4 helper T cells. Thus, data from a number of trials indicates that adoptively transferred T cells can persist for extended times. However, detailed kinetic studies have not yet been performed and it is not yet known if the intermitotic survival times of the transferred cells are the same as for their normal lymphocyte counterparts.
Together, the above studies indicate that limited in vivo survival of adoptively transferred T cells can occur for multiple reasons. Novel approaches to use genetic engineering may enhance the survival of adoptively transferred T cells. 40, 58 Presently, genetic marking is the only technique that can be used in clinical studies to determine engraftment and survival parameters of adoptively transferred T cells. However, combinations of new approaches using complementarity region (CDR3) size spectratyping and high-resolution magnetic imaging using T cells labeled with physiologically inert nanoparticles should enable studies of adoptively transferred T cells in the absence of genetic marking.
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Therapeutic acceleration of T-cell recovery after SCT
A number of promising strategies involving adoptive cell therapy are being explored in the setting of SCT. T-cell subsets are perturbed for months to years after SCT, 62 and the T-cell repertoire as assessed by CDR3 spectratyping is constricted and unstable after SCT. 63 Lymphoid reconstitution for the first several months after autologous SCT is due to the passenger T cells present in the stem cell graft. 64 Clinical attempts to accelerate T-cell recovery after SCT have included both in vivo stimulation by exogenous cytokines and adoptive transfer of mature T cells (Table 2) .
Enhanced immune reconstitution with exogenous cytokines
Studies using IL-2 after autologous SCT have included relatively small numbers of patients but have demonstrated that IL-2 can be given safely. [65] [66] [67] Higher doses have resulted in increased lymphocytosis; 5 for instance, one study demonstrated an increase in median lymphocyte counts from 500 to 2500 Â 10 6 /l after 22 days of treatment. 5 Lower doses of IL-2 seem to enhance NK cell number without a significant effect on T-cell number. 67, 68 Although impressive DFS rates of up to 70% have been reported after autologous SCT for AML followed by IL-2, 65,66 these trials included very small numbers of patients with relatively short follow-up, and enhancement of autologous GVL activity by exogenous IL-2 remains to be defined. The role of IL-2 to enhance allogeneic T-cell function has also been studied in small numbers of patients. Soiffer et al 69 administered low-dose IL-2 to 29 recipients of T-cell depleted allogeneic bone marrow grafts and found that NK cells were markedly increased while T-cell numbers were relatively unchanged. Impressive DFS rates compared to historical controls were reported in patients treated with IL-2. Perhaps, the best evidence that IL-2 enhances donor T-cell function after allogeneic SCT comes from reports demonstrating that patients who fail to respond to donor leukocyte infusions (DLI) for relapsed disease may achieve complete remission after the addition of IL-2. Slavin et al 70 reported that several patients with acute or chronic leukemia failed DLI but achieved CR after the addition of IL-2 or a combination of IL2 plus IL-2-activated donor T cells. Nadal et al 71 described five of 13 patients who had failed DLI and subsequently responded to the addition of IL-2. Although these observations are intriguing, the role of IL-2 when added to DLI remains to be demonstrated.
Enhanced immune reconstitution though adoptive transfer of T cells
An alternative strategy to enhance T-cell reconstitution and function is to administer ex vivo activated T cells. However, most techniques to enhance T-cell activity or numbers are limited by the lack of available T cells in heavily pre-treated patients (in an autologous setting), or by the lack of an effective ex vivo culture method. We have developed a novel culture system that uses CD3 and CD28 antibody coated magnetic beads to serve as artificial antigen-presenting cells; by engaging CD3 with the costimulatory signal for CD28, CD4
þ T cells can be expanded several thousand fold and used for adoptive immunotherapy. 34, 72, 73 This technique avoids possible tolerance induction that can occur when the T-cell receptor is activated without proper costimulation and may bypass innate in vivo tumor-or cytokine-induced T-cell suppression. In addition, expansion through costimulation provides activated T cells with a diverse T-cell repertoire to accelerate immune reconstitution. Manipulation of the culture conditions can enhance Th1 or Th2 CD4 cell functions. 21, 74, 75 We have recently completed a phase I study of autologous SCT followed by infusions of ex vivo expanded costimulated T cells for patients with relapsed or refractory NHL and determined that (1) the administration of up to 1 Â 10 10 CD3 þ cells is safe and feasible and (2) these cells result in both a dosedependent increase in day 30 lymphocyte counts, an increase in Th1 cell function as assessed by interferon-g secretion, and a delayed leukocytosis. 21 Larger studies will determine if these effects translate into improved outcomes after autologous SCT.
In a similar randomized phase I/II trial, 52 patients with multiple myeloma have undergone autologous SCT followed by adoptive transfer of costimulated expanded autologous T cells. 76 T-cell numbers were significantly higher in recipients of T-cell infusions compared to patients who did not received expanded T cells. Studies are in progress to determine if these infusions will speed the immune response to vaccination, and improve the overall outcome.
Allogeneic adoptive immunotherapy
Ex vivo costimulation may be especially useful in the setting of allogeneic SCT. Donor T cells have the potential to generate a potent GVT response, best documented through the use of DLI to treat relapse after allogeneic stem cell grafting. 77 However, GVL induction seems to be diseasespecific; it is most effective for relapsed CML and less effective for other malignancies. The actual mechanisms for disease resistance to DLI are not known. It is possible that donor T cells are not appropriately activated in vivo to induce an antitumor effector response. To explore the feasibility and toxicity of adoptive immunotherapy with activated allogeneic T cells, we have conducted a trial of DLI followed by escalating doses of ex vivo costimulated donor T cells (activated, or 'aDLI') for patients with relapse after allogeneic SCT. At doses of aDLI from 1 Â 10 6 to 1 Â 10 8 CD3 þ cells/kg, preliminary data show that aDLI is well tolerated without excessive GVHD and response rates are impressive in diseases that historically have not responded well to DLI. 78 Furthermore, preliminary functional assays show that immunity against pathogens such as EBV and CMV is retained after aDLI, suggesting that this approach for T-cell expansion may restore antiviral while inducing antileukemia immunity.
In addition to promoting immune reconstitution through adoptive transfer of T cells, or through in vivo cell stimulation, it may be possible to accelerate T-cell recovery by enhancing thymopoiesis after SCT. For instance, keratinocyte growth factor (KGF) can protect stromal elements in the thymus that are required for T-cell development. Stromal elements in the thymus appear to be targets for GVHD; if these are damaged, normal thymopoiesis cannot occur. This may partially explain why T cells are particularly sensitive to the GVH reaction, and why GVHD itself results in significant immunosuppression. Rossi et al 79 have shown that KGF can bind to thymic stromal elements and protect against GVHDinduced thymic damage; KGF treated mice had preserved T-cell development compared to mice who did not receive KGF. KGF has been tested clinically to prevent mucositis after autologous SCT, 80 and effects on T-cell recovery in the setting of clinical autologous and allogeneic SCT will be quite interesting. An alternative approach to enhance T-cell development is with the use of IL-7. IL-7 is critical for Tcell development, homeostasis and effector functions. 81, 82 In mice transplanted with T-cell depleted marrow grafts, IL-7 enhanced thymopoiesis, though this resulted in increased toxicity from GVHD if the graft contained T cells. 83 In a primate transplant model, IL-7 induced a marked increase in peripheral T-cell numbers. In these studies, the effect of IL-7 on thymopoiesis was unclear and therefore the effects on long-term immune reconstitution are uncertain. 84 Nevertheless, IL-7 may ultimately prove to be a useful clinical agent to increase numbers of peripheral memory and naı¨ve T cells, and hence may have the potential to enhance responses to adoptive cell transfer and therapeutic vaccination. Future studies should define the role of IL-7 in clinical SCT, particularly when the donor graft is T cell depleted.
Concluding remarks
New therapies and better supportive care continue to improve outcomes after autologous and allogeneic SCT. Nevertheless, delayed immune reconstitution and disease recurrence remain major limitations to the outcome and wide spread application of stem cell therapies. Rapidly accumulating information regarding T-cell biology, function and survival is leading to newer approaches of cellular immunotherapy (Table 3) . New methods to manipulate T cells ex vivo can now enhance the function of effector T cells, promote their survival, and may ultimately lead to improved clinical outcomes and new applications for patients undergoing hematopoietic stem cell transplantation. Table 3 Future considerations for adoptive cell therapy 1. Increasing use of 'host conditioning' to improve homeostatic proliferation and decrease host suppressive cells 2. Prevention or control of GVHD through regulatory T-cell infusions and/or mesenchymal stem cell infusions 3. Efficient genetic retargeting of engineered T cells by introduction of chimeric receptors 4. Use of artificial APC such as anti-CD3/CD28 beads to efficiently activate T cells 5. Rejuvenation of T cells through enforced expression of CD28 or telomerase 6. Restoration or preservation of thymic function with KGF-1 or IL-7
